CreatorsPublishersAdvertisers

#Bmrn

The Smartest Stocks to Buy With $250 Right Now

There's no such thing as a bad time to buy into great businesses if you have a long-term mindset. This stock trio offers sustainable double-digit growth potential and exceptional value. For the past 19 months, Wall Street and investors have enjoyed an epic stock market rally. Since the widely followed...
STOCKS
Picture for The Smartest Stocks to Buy With $250 Right Now
modernreaders.com

$431.86 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter

Wall Street analysts expect that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will post $431.86 million in sales for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for BioMarin Pharmaceutical’s earnings. The highest sales estimate is $447.00 million and the lowest is $413.30 million. BioMarin Pharmaceutical posted sales of $476.78 million during the same quarter last year, which indicates a negative year over year growth rate of 9.4%. The business is expected to report its next quarterly earnings results after the market closes on Wednesday, October 27th.
FINANCIAL REPORTS
Picture for $431.86 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter
modernreaders.com

Dimensional Fund Advisors LP Purchases 28,376 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

A number of other hedge funds have also recently added to or reduced their stakes in the business. Ameriprise Financial Inc. increased its holdings in BioMarin Pharmaceutical by 43.0% during the 1st quarter. Ameriprise Financial Inc. now owns 6,233,335 shares of the biotechnology company’s stock worth $470,682,000 after purchasing an additional 1,873,040 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in BioMarin Pharmaceutical by 29.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,755,379 shares of the biotechnology company’s stock worth $313,348,000 after purchasing an additional 847,367 shares in the last quarter. Palo Alto Investors LP increased its holdings in BioMarin Pharmaceutical by 2.4% during the 1st quarter. Palo Alto Investors LP now owns 2,205,750 shares of the biotechnology company’s stock worth $166,556,000 after purchasing an additional 50,700 shares in the last quarter. Manning & Napier Group LLC increased its holdings in BioMarin Pharmaceutical by 1.3% during the 2nd quarter. Manning & Napier Group LLC now owns 1,727,384 shares of the biotechnology company’s stock worth $144,131,000 after purchasing an additional 22,542 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in BioMarin Pharmaceutical by 2.6% during the 1st quarter. Northern Trust Corp now owns 1,214,996 shares of the biotechnology company’s stock worth $91,744,000 after purchasing an additional 30,432 shares in the last quarter. Hedge funds and other institutional investors own 94.44% of the company’s stock.
STOCKS
Picture for Dimensional Fund Advisors LP Purchases 28,376 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
TRENDING TOPICS

Pomerantz Law Firm Announces The Filing Of A Class Action Against BioMarin Pharmaceutical Inc. And Certain Officers - BMRN

NEW YORK, Oct. 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (BMRN) - Get BioMarin Pharmaceutical Inc. Report and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
BUSINESS
modernreaders.com

BioMarin Pharmaceutical (BMRN) to Release Earnings on Wednesday

BioMarin Pharmaceutical (NASDAQ:BMRN) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, October 27th. Analysts expect BioMarin Pharmaceutical to post earnings of ($0.12) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
MEDICAL & BIOTECH
analystratings.com

The CEO of BioMarin Pharmaceutical is Exercising Options

Based on BioMarin Pharmaceutical’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $502 million and quarterly net profit of $12.94 million. In comparison, last year the company earned revenue of $429 million and had a GAAP net loss of $29.18 million. The company has a one-year high of $92.57 and a one-year low of $71.65. BMRN’s market cap is $13.77 billion and the company has a P/E ratio of 17.40.
MEDICAL & BIOTECH
modernreaders.com

Ossiam Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Ossiam lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 108.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,057 shares of the biotechnology company’s stock after purchasing an additional 1,588 shares during the period. Ossiam’s holdings in BioMarin Pharmaceutical were worth $235,000 as of its most recent SEC filing.
STOCKS
rivertonroll.com

Bridgewater Associates LP Boosts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Bridgewater Associates LP boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 72.5% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 23,181 shares of the biotechnology company’s stock after acquiring an additional 9,743 shares during the quarter. Bridgewater Associates LP’s holdings in BioMarin Pharmaceutical were worth $1,934,000 as of its most recent filing with the SEC.
STOCKS
theenterpriseleader.com

Geode Capital Management LLC Purchases 140,877 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Geode Capital Management LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 6.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,308,922 shares of the biotechnology company’s stock after acquiring an additional 140,877 shares during the quarter. Geode Capital Management LLC owned 1.26% of BioMarin Pharmaceutical worth $192,379,000 as of its most recent SEC filing.
STOCKS
WKRB News

Healthcare of Ontario Pension Plan Trust Fund Increases Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

A number of other hedge funds and other institutional investors have also made changes to their positions in BMRN. GWM Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 2.2% in the 2nd quarter. GWM Advisors LLC now owns 6,356 shares of the biotechnology company’s stock valued at $530,000 after buying an additional 139 shares during the period. Torray LLC grew its stake in shares of BioMarin Pharmaceutical by 0.9% in the 2nd quarter. Torray LLC now owns 16,199 shares of the biotechnology company’s stock valued at $1,352,000 after buying an additional 142 shares during the period. Kistler Tiffany Companies LLC grew its stake in shares of BioMarin Pharmaceutical by 15.1% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 1,080 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 142 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of BioMarin Pharmaceutical by 0.5% in the 2nd quarter. Commonwealth Equity Services LLC now owns 31,626 shares of the biotechnology company’s stock valued at $2,638,000 after buying an additional 156 shares during the period. Finally, HighTower Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 4.5% in the 1st quarter. HighTower Advisors LLC now owns 4,192 shares of the biotechnology company’s stock valued at $319,000 after buying an additional 179 shares during the period. 94.44% of the stock is owned by institutional investors.
MARKETS
modernreaders.com

Analysts Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Price Target at $102.30

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been given an average recommendation of “Buy” by the twelve ratings firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $102.30.
MEDICAL & BIOTECH
mainebiz.biz

JAX names California biotech veteran as president and CEO, succeeding Edison Liu

Bar Harbor-based Jackson Laboratory has named a biotech industry leader and human genetics researcher, Lon Cardon, to succeed Dr. Edison Liu next month as president and CEO. Liu, who has directed the internationally prominent biomedical research institution for a decade, announced earlier this year that he would be stepping down from that role in February 2022. Cardon will become president and CEO on Nov. 29, according to a JAX news release Monday afternoon.
MEDICAL & BIOTECH
WKRB News

Brokerages Anticipate BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Will Announce Earnings of $0.33 Per Share

Wall Street brokerages expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings per share of $0.33 for the current quarter, according to Zacks. Nine analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with the highest EPS estimate coming in at $0.38 and the lowest estimate coming in at $0.27. BioMarin Pharmaceutical reported earnings per share of $0.54 in the same quarter last year, which would suggest a negative year over year growth rate of 38.9%. The company is scheduled to issue its next earnings report on Thursday, November 4th.
FINANCIAL REPORTS
rivertonroll.com

JPMorgan Chase & Co. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

JPMorgan Chase & Co. increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 29.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,755,379 shares of the biotechnology company’s stock after purchasing an additional 847,367 shares during the period. JPMorgan Chase & Co.’s holdings in BioMarin Pharmaceutical were worth $313,348,000 as of its most recent SEC filing.
STOCKS
WKRB News

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Korea Investment CORP

Korea Investment CORP grew its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 7.6% in the second quarter, HoldingsChannel reports. The fund owned 43,800 shares of the biotechnology company’s stock after buying an additional 3,100 shares during the quarter. Korea Investment CORP’s holdings in BioMarin Pharmaceutical were worth $3,655,000 at the end of the most recent quarter.
STOCKS
YOU MAY ALSO LIKE